Abstract
Steroidogenic enzyme type 3 17β-hydroxysteroid dehydrogenase (17β-HSD) is an important therapeutic target for androgen-sensitive diseases. This enzyme selectively reduces the C17 ketone of 4-androstene-3,17-dione (Δ4-dione), thus producing testosterone (T) using NADPH as cofactor. Our group previously synthesized hybrid (estradiol/adenosine) inhibitors that successfully inhibit the biosynthesis of the potent estrogen estradiol by type 1 17β-HSD. To similarly lower the level of the potent androgen testosterone, inhibitors of type 3 17β-HSD were designed and synthesized applying the same hybrid (substrate/cofactor) strategy. Two chemical approaches were developed to join the three components of the bisubstrate inhibitor (the substrate Δ4-dione, an alkyl spacer and the cofactor moiety adenosine). An alkylation in the α position of steroidal 17-ketone or a cross-metathesis was used as a key step to efficiently join the substrate and the alkyl spacer, whereas an esterification was employed to link the spacer to adenosine. An enzymatic assay in homogenated HEK-293 cells overexpressing type 3 17β-HSD revealed that the best inhibitors of that series are those bearing an alkyl side-chain spacer of 11 or 12 methylenes: inhibition of 69 and 78% at 1 μM were respectively observed. As expected, these bisubstrate inhibitors were less potent in intact cells than in homogenated cells. However, both enzymatic assays revealed that the strategy of substrate/cofactor dual inhibitors seems to work for type 3 17β-HSD, although the inhibitors designed have not been optimized yet.
Keywords: crossmetathesis, androgen, hormone, steroid, type 3 17β-HSD, 17β-hydroxysteroid dehydrogenase, enzyme, Inhibitor
Medicinal Chemistry
Title: Design, Synthesis and In Vitro Evaluation of 4-Androstene-3,17-dione/Adenosine Hybrid Compounds as Bisubstrate Inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase
Volume: 2 Issue: 4
Author(s): Marie Berube, Yannick Laplante and Donald Poirier
Affiliation:
Keywords: crossmetathesis, androgen, hormone, steroid, type 3 17β-HSD, 17β-hydroxysteroid dehydrogenase, enzyme, Inhibitor
Abstract: Steroidogenic enzyme type 3 17β-hydroxysteroid dehydrogenase (17β-HSD) is an important therapeutic target for androgen-sensitive diseases. This enzyme selectively reduces the C17 ketone of 4-androstene-3,17-dione (Δ4-dione), thus producing testosterone (T) using NADPH as cofactor. Our group previously synthesized hybrid (estradiol/adenosine) inhibitors that successfully inhibit the biosynthesis of the potent estrogen estradiol by type 1 17β-HSD. To similarly lower the level of the potent androgen testosterone, inhibitors of type 3 17β-HSD were designed and synthesized applying the same hybrid (substrate/cofactor) strategy. Two chemical approaches were developed to join the three components of the bisubstrate inhibitor (the substrate Δ4-dione, an alkyl spacer and the cofactor moiety adenosine). An alkylation in the α position of steroidal 17-ketone or a cross-metathesis was used as a key step to efficiently join the substrate and the alkyl spacer, whereas an esterification was employed to link the spacer to adenosine. An enzymatic assay in homogenated HEK-293 cells overexpressing type 3 17β-HSD revealed that the best inhibitors of that series are those bearing an alkyl side-chain spacer of 11 or 12 methylenes: inhibition of 69 and 78% at 1 μM were respectively observed. As expected, these bisubstrate inhibitors were less potent in intact cells than in homogenated cells. However, both enzymatic assays revealed that the strategy of substrate/cofactor dual inhibitors seems to work for type 3 17β-HSD, although the inhibitors designed have not been optimized yet.
Export Options
About this article
Cite this article as:
Berube Marie, Laplante Yannick and Poirier Donald, Design, Synthesis and In Vitro Evaluation of 4-Androstene-3,17-dione/Adenosine Hybrid Compounds as Bisubstrate Inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase, Medicinal Chemistry 2006; 2 (4) . https://dx.doi.org/10.2174/157340606777724086
DOI https://dx.doi.org/10.2174/157340606777724086 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents on Enhancing the Potency and Longevity of Highly Valuable Protein Hormones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery TRPM8: From Cold to Cancer, Peppermint to Pain
Current Pharmaceutical Biotechnology siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Current Cancer Therapy Reviews Recent Advances in Synthesis and Identification of Cyclic Peptides for Bioapplications
Current Topics in Medicinal Chemistry Pre-Clinical and Clinical Evaluation of Nuclear Tracers for the Molecular Imaging of Vulnerable Atherosclerosis: An Overview
Current Medicinal Chemistry Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Leukocyte-Independent Effects of CC-Chemokines on Vascular Remodeling
Current Pharmaceutical Biotechnology Perspectives of Choroidal Neovascularization Therapy
Current Drug Targets The Synthesis and Anticancer Potentials of Quinoline Analogues: A Review of Literature
Mini-Reviews in Organic Chemistry Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594
Current Pharmaceutical Biotechnology Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Review of Novel Aspects of the Regulation of Ghrelin Secretion
Current Drug Metabolism Use of Transgenic Mice as Models for Prostate Cancer Chemoprevention
Current Molecular Medicine Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Pharmaceutical Nanotechnology United States Patent Watch (April – June 2015)
Pharmaceutical Nanotechnology Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Virtual Screening of NCI Diversity Set II Lead to New Cyclin-Dependent Kinases 5 Inhibitors Using AutoDock
Letters in Drug Design & Discovery Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience